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In this study, we have taken advantage of the unique property of a potent dendritic cell (DC) growth factor, Flt-3 ligand (FL), which could act
as a vaccine adjuvant. Accordingly, a single injection of plasmid DNA coding for soluble FL (FLex) was shown to induce large numbers of DCs in
various tissue compartments and was critical for generating high frequencies of antigen-specific (HIV gp120 and LCMV NP) immune responses
in mice. Interestingly, this enhanced level of immune response is strictly dependent on the co-delivery (i.m.) of the DNAvaccines and hFLex DNA
to mice harboring large numbers of DCs. The high frequencies of antigen-specific CD8+ T cells were largely associated with the expansion phase
of DCs in vivo. However, DC expansion and immune enhancement have not reciprocally maintained a linear correlation, suggesting that other
factors, cytokines/chemokines, which have the potential to modulate the microenvironment of DCs, could influence immunological outcome in
this vaccination modality.
© 2006 Elsevier Inc. All rights reserved.Keywords: Human FL; Dendritic cells; HIV gp120; T cell mediated Immune responses; anti gp120 Ab; LCMVIntroduction
DNA vaccination is a simple and elegant means of inducing
T cell and antibody responses in a number of animal model
systems (Amara et al., 2001; Barouch et al., 2000; Gurunathan
et al., 2000; Kirman and Seder, 2003). Although DNA vaccines
deliver antigens to DCs and other professional antigen-
presenting cells (APC) for T cell activation (Akbari et al.,
1999; Condon et al., 1996; Kirman and Seder, 2003; Porgador
et al., 1998), this mode of antigen delivery is not very efficient
and induces only sub-optimal levels of immune response. This
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doi:10.1016/j.virol.2006.02.016such as DCs that could be transfected by naked DNA and also
their inability to engage innate immune effector mechanisms
that are critical for the generation of adaptive immunity
(Gurunathan et al., 2000; Kirman and Seder, 2003; Leitner et
al., 2003; Restifo et al., 2000; Rodriguez and Whitton, 2000).
Since DNA vaccines mimic viral infections accessing the MHC
class I (CD8 T cells) and MHC class II (CD4 T cells) pathways
of APC, the methods for optimizing vaccine efficacy remain an
important goal and would provide further insight into the design
of efficacious vaccines against a multitude of pathogens or
tumors (Gurunathan et al., 2000; Kirman and Seder, 2003;
Maloy et al., 2001; Restifo et al., 2000; Rodriguez and Whitton,
2000; Leifert et al., 2004).
DCs play a central role in the orchestration of the primary
and memory phases of the immune response (Banchereau and
Steinman, 1998; Bhardwaj, 2001; Pulendran, 2004; Shortman
and Liu, 2002; Steinman and Pope, 2002). In spite of their low
abundance (0.5–1%) in the peripheral tissues, DCs are the most
potent APC that have the remarkable ability to express/capture
antigens for presentation to T cells in the secondary lymphoid
organs of the immune system (Banchereau and Steinman
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cytokines/chemokines that regulate the number and differenti-
ation of DCs in vivo, fms-like tyrosine kinase 3 (Flt-3) ligand
(FL), a hematopoietic growth factor, has the unique ability to
promote the induction of large numbers of DCs and NK cells
(Maraskovsky et al., 1996, 2000; Pulendran et al., 1998, 2000).
FL exists either as a membrane-bound or secreted-soluble
protein and both molecular forms are functional (Hannum et al.,
1994; Lyman et al., 1994). The resolution of X-crystal structures
of soluble FL has revealed that it could exist as a dimeric protein
with novel protein folds (Savvides et al., 2000).
Importantly, the majority of studies were done with
recombinant soluble human FL (hFLex, FL extracellular
portion of FL), and this soluble form of FL was highly active
in expanding DCs in mice, monkeys and humans (Fong et al.,
2001; Gregory et al., 2001; Maraskovsky et al., 1996, 2000;
Merad et al., 2002; Parajuli et al., 2001; Pulendran, 2004;
Pulendran et al., 2000; Sumida et al., 2004; Coates et al., 2003).
Such increases in DC number had beneficial effects on vaccine-
induced immune responses against microorganisms and tumors
(Fong et al., 2001; Gregory et al., 2001; Merad et al., 2002;
Parajuli et al., 2001; Sumida et al., 2004). Recent studies have
also assessed the potency of plasmid-encoded Flt-3 ligand (FL
and FLex) on DC expansion and host immunity (Fong et al.,
2001; Moore et al., 2002; Mwangi et al., 2002; Peretz et al.,
2002; Sailaja et al., 2003).
In the present study, we performed experiments to test the
hypothesis that large numbers of DCs would prime the
immune system with enhanced potency. Accordingly, we have
carried out DNA vaccination in the presence of large and
normal (homeostatic) levels of DCs. We used plasmid-
encoded FLex DNA for DC expansion in vivo, and two
viral proteins (HIV-1 gp120 and LCMV NP) as DNA vaccine
antigens to test our hypothesis. HIV-1 gp120 is a poorly
immunogenic soluble protein, and LCMV NP is a highly
immunogenic protein from lymphotropic choriomeningitis
virus (LCMV). The results of our experiments showed that
simply expanding DC numbers, although necessary, was not
sufficient to induce enhanced levels of both T cell and
antibody responses, and that other factors (cytokines and
chemokines) that regulate the function of the FL-expanded
DCs could play critical roles in inducing the enhanced levels
of antigen-specific immune responses in mice.
Results
Kinetics of DC expansion in vivo by FLex DNA and their
maturation status
Previously, we and others have used the hydrodynamic
delivery method to induce large numbers of DCs in mice (He et
al., 2000; Liu et al., 1999; Sailaja et al., 2003). In the current
study, we examined the kinetics of DC expansion (CD11b+ and
CD11c+ cells). Lineage-negative cell populations from various
tissues were stained for the expression of CD11c and CD11b
and analyzed on FACS (Fig. 1A). The percentage of CD11b+
and CD11c+ cells showed steady increases at different times inresponse to FLex DNA. For example, the bone marrow (BM)
showed the earliest and significant increases (13×) in this
population of cells followed by spleen (8–9×), LN (8×), PBMC
(7×), compared to the vector control at day 7. This in vivo
expansion was only transient, as evidenced by normal DC
numbers returning after day 18 (Fig. 1A). This is consistent with
Flt-3 L engaging the receptor, Flt-3, on hematopoietic stem cells
in the BM (Maraskovsky et al., 1996, 2000).
DNA sequences, especially those having the CpG motif in
proper sequence context, have the propensity to induce the
maturation of DC. Since we had used FLex DNA in our
experiments, we wanted to ascertain the activation status of DCs
by examining the expression profiles of co-stimulatory
molecules, CD80 and CD86 and other surface molecules,
MHC Class-II, CD1d, CD205 and CD40. As shown in Fig. 1B,
there is little or no difference in the levels of CD80, CD86,
MHC Class-II, and CD1d in spleenic DCs of the control or
FLex-treated mice, with CD40 and CD205 showing only slight
increases due to FLex treatment. Thus, these experiments
demonstrate that the FL protein expressed from FLex DNAwas
very effective in inducing the expansion of predominantly
immature DCs, a cardinal feature to elicit optimal immune
responses to vaccines or infection (Banchereau and Steinman,
1998; Pulendran, 2004; Shortman and Liu, 2002; Steinman and
Pope, 2002).
In vivo DC expansion is necessary, but not sufficient to
enhance gp120-specific CD8+ T cell and antibody responses
Our primary hypothesis is that large numbers of DCs would
be amenable to DNA transfection in vivo, and thereby
enhancing the immunogenicity of DNA vaccines. To test this
notion, we have used the protocol as enumerated in Fig. 2. This
protocol was designed to assess the primary and booster phases
of the immune response in individual mice, providing a
longitudinal snapshot of the generation and subsequent
evolution of the immune response. In this set of experiments,
we have used five groups (A to E) of mice (5 per group) (Figs.
2A and B). The mice in all five groups received the equal
amounts of plasmid DNA (10 μg of empty (sham) vector or
FLex DNA (DC expansion), and 50 μg of DNAvaccine, gp120
and 50 μg of sham vector or FLex DNA). The mice in group A
(negative control) received the empty vector in both the
primary and booster phases of DNA immunization. The mice
in groups B and C were immunized (i.m.) with gp120 DNA
plus empty vector (B), gp120 DNA plus FLex DNA (C), and
these experiments were done in the absence of DC expansion
(sham vector, i.v.). Finally, the mice in groups D and E were
immunized (i.m.) with gp120 DNA plus empty vector (D), and
gp120 DNA plus FLex DNA (E), and the immunization was
performed in the presence of DC expansion (FLex DNA, i.v.).
The mice in groups B, C, D, and E were boosted with gp120
DNA at day 35 after the primary immunization. We chose day
3 of FLex DNA injection to assess the adjuvant effects of
plasmid-encoded FLex on DNA vaccine-induced immune
responses, as this time point corresponds to the appearance
of FLex-expanded DC in the various tissues of mice (Fig. 1A).
. 1. (A) Kinetics of expansion of DC subsets (CD11c+CD11b+) in mice injected with FLex DNA expressing soluble human Flt-3 L: Mice were injected with FL DNA by the hydrodynamics-based DNA delivery
tem (Liu et al., 1999). At different days after i.v. injection, lineage negative cell populations in the various tissue compartments (BM, LN, Spleen, PBMC) were ined for the expression of CD11b+ and CD11c+ as
cribed under Materials and methods. The percentages of CD11c+ DCs for the control and FLex DNA-treated mice are given. For control mice, the day 7 sample is en and for the treated groups, the samples for days
and 7, 18 are indicated. We used three mice for each group to assess the consistency of the expanded DC population, as described previously by Sailaja et al. (20 ). (B) Phenotype of the expanded CD11b+CD11c+
subsets: An aliquot of the day 7 sample from spleenic DCs of the control and FLex DNA-treated mice was stained for cell surface markers, CD1d, CD80, CD86, C 40, MHC II or CD205, and was analyzed on an F-1
nnel. Representative data of two independent experiments are given here.
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Fig. 1 (continued ).
Fig. 2. Immunization protocol to assess vaccine efficacy in the presence of normal and large numbers of DCs in mice: We chose five groups of mice (A to E, 5 mice per
group) for immunization with the empty vector (A) or the DNAvaccine expressing HIV-1 gp120 (B to E). Three groups of mice (A to C) received the empty vector i.v.
(no DC expansion) at day minus 3 (day −3) and two groups of mice (D and E) were injected with FLex DNA (10 μg, DC expansion) at the same time. Three days (day
0) after the i.v. injections of empty vector or FLex DNA, the mice were injected with the vector alone (100 μg) (A) or co-injected with gp120 DNA (50 μg each) (B and
D). Groups C and E were immunized with DNA construct expressing the gp120 (50 μg) and FLex (50 μg) proteins. This vaccination protocol ensures that each mouse
in all groups received the equivalent amount of DNA and is critical for the assessment of vaccine efficacy between groups in the study. For the boost response, the
groups (B to E) received gp120 DNA (100 μg) on day 35, except group A (received equal quantity of vector DNA). The immunization was carried out by needle
injection (i.m.) of the mice. The gp120-specific CD8+ T cells making IFN-γ and ELISA antibody titers were measured in the control and immunized mice as described
previously by Sailaja et al. (2003).
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cells in the primary and booster phases of the immune response
in representative mice in all five groups (A to E). DNA gp120
vaccine induced gp120-specific CD8+ T cells (B to E), and as
expected, no mice in group A had any detectable levels of
gp120-specific CD8+ T cells. Interestingly, during the primary
immunization phase, we observed differences in the frequency
of gp120-specific CD8+ T cells. For example, a mouse from
group E harbored high frequencies of gp120-specific CD8+ T
cells, compared to that from of each of the other three groups.
This number was reduced at day 30 in all four groups of mice,
and likely reflects a well-defined contraction phase observed in
many acute viral infections (Murali-Krishna et al., 1998; Kaech
et al., 2002). A booster injection revealed an interesting feature
in each of the vaccination regimens (B to E). The mice in groups
B, C and D harbored very similar levels of gp120-specific CD8+
T cells irrespective of the DC expansion status (Fig. 3A and B).
Note that group D received FLex DNA (i.v.) to expand DCs in
vivo, and the mice in groups C were injected with FLex DNA
(i.m.) at the time of gp120 DNA vaccine delivery.
Importantly, however, the mice in group E harbored
significantly high frequencies of gp120-specific CD8+ T cells
with a representative mouse in this group reaching nearly 9% of
the antigen-specific CD8+ T cell population (Fig. 3A). Also,
among the four experimental groups (B to E), only group E
induced relatively high frequencies of antigen-specific CD8+ T
cells during the priming phase of the immune response as well,
indicating that this modality of vaccination appears to be
effective in the induction of high levels of cell-mediated
immune responses even during the very early primary phase of
DNA vaccination. The histograms with a standard error of the
mean (n = 5) of different groups from a representative
experiment is displayed in Fig. 3B. These experiments have
demonstrated that DC expansion is necessary, but not sufficient
to induce the enhanced levels of antigen-specific CD8+ T cells
and that the co-administration of FLex DNA and gp120 DNA is
required to achieve this outcome, thereby revealing an adjuvant
activity of plasmid-encoded FLex in mice (compare group D
with group E).
HIV-1 gp120 is a secreted protein and will be able to elicit
antibodies through CD4+ T cell help (Rodriguez and Whitton
(2000)). We analyzed the production of gp120-specific
antibodies in the same groups of mice (groups A to E)
used for CD8+ T cell responses. Fig. 3C shows the pooled
antibody titers from a representative experimental group
during the primary and booster phases of the immune
response. As expected, the control group did not elicit any
gp120-specific antibody response. However, the immunized
groups (groups C to E) showed antibody titers only after
booster injections, but the group E mice contained antibody
titers 3–4 times higher than those in the other two groups of
mice (C and D). Again, as with the cellular immune responses
(CD8+ T cells), co-injection of FLex DNA and gp120 DNA
was essential to induce enhanced levels of antibody responses
in mice that harbored large numbers of DCs, revealing the
adjuvant activity of FLex in muscle cells in genetic
immunization.Enhanced CD8+ T cell response correlates with the kinetics of
DC expansion in vivo
In the experiments described in Fig. 3, we chose day 3 after
the injection of FLex DNA to immunize mice. It is clear that DC
expansion is not complete at this time and continues to occur
reaching higher levels around 7–8 days (Fig. 1A). We therefore
wanted to examine what would be the critical time during this
phase of DC expansion that is optimal for assessing the adjuvant
activity of plasmid-encoded FLex. To address this issue, we set
up the same vaccination protocol that we used for group E (Figs.
2 and 3A), but performed DNA vaccination of mice at different
times (days) after the delivery (i.v.) of FLex DNA to induce DC
expansion. Accordingly, we set up the protocol to immunize
mice (Fig. 4A), and individual mice were bled as before to
assess the frequencies of CD8+ T cells expressing INF-γ in
PBMC. The mean with standard error of the mean from five
mice in each group was shown in a histogram (Fig. 4C). This
experimental design has revealed that the high frequencies of
gp120-specific CD8+ T cells were achieved up to 7 days after
the injection of FLex DNA. Interestingly, the adjuvant activity
of plasmid-encoded FLex is no longer seen at day 10 post FLex
delivery. At this time, the frequency of gp120-specific CD8+ T
cells is comparable to that induced by control plasmids (gp120
DNA). Note that the percentages of antigen-specific CD8+ T
cells are variable, but the extent of the difference (3- to 4-fold)
was maintained in both sets of experiments (Figs. 3 and 4).
Taken together, these data suggest that the immune (CD8+ T
cell) enhancement in response to DNA vaccines is associated
with Flt3-L-induced expansion of DCs. However, the role of
other factors (cytokines and chemokines) that modulate the
functional capacity of the immune cells could not be ruled out
because of the fact that these two processes (DC expansion and
immune enhancement) have not strictly maintained a linear
correlation in vivo (Figs. 1, 3 and 4).
Persistence and longevity of gp120-specific CD8+ T cells
An effective vaccination protocol has to induce immune
responses that could persist long-term in animals (Kaech et al.,
2002). To test this possibility, we rested the vaccinated mice in
groups B, D and E (Fig. 3A) for 60 days after a single booster
injection before analyzing their PBMC for antigen-specific
CD8+ T cells (Figs. 5A, B). The frequency of gp120-specific
CD8+ T cells in group E mice had reduced to 5.1% from the
peak levels of 9% at day 12 after a booster injection. That is,
nearly 60% of antigen-specific CD8+ T cells are still persisting
in this group of mice, compared to 25% and 40% respectively in
groups B and D. The differences in the frequencies of memory
CD8+ T cells directly correlate with the extent and degree of
expansion achieved during the boost response in different
groups of mice (Fig. 4). Thus, our study is consistent with the
notion that the generation and maintenance of memory T cell
pools are dependent on the magnitude of the effectors generated
during the expansion phase of the immune response (Betts et al.,
2001; Haglund et al., 2002; Kaech et al., 2002; Murali-Krishna
et al., 1998).
Fig. 3. DC expansion in vivo and vaccination (i.m.) with the two plasmids, gp120 DNA and Flex DNA, are required to enhance T-cell and antibody responses: PBMC
from the control and immunized mice were pulsed with the gp120 peptide in a short-term incubation (6 h) to assess the percentage of CD8+ INF-γ T cells during the
primary and booster phases of DNAvaccination as described previously by Nayak et al. (2003). (A) The percentage of CD8+ T cells making IFN-γ in response to the
gp120 peptide. Representative flow plot form each group (groups A to E) displaying IFN-γ staining. (B) The average frequencies of gp120-specific CD8+ T cells in 5
mice in each of the five groups. The vaccination data presented in the study represent one of two independent experiments (5 mice per group). The bar represents the
standard error of the mean. P < 0.05. (C) gp120 antibody titers: Pooled sera (5 mice per group) were assessed for antibodies specific to gp120 as described previously
by Sailaja et al. (2003). Blood was collected for serum isolation at days 14, and 30 during the primary immune response phase, and at day 12 after booster injection.
Representative data from one experiment (of two repeat) are presented.
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in mice
To provide further evidence for this vaccine concept, we
used the plasmid expressing LCMV NP, a prototypic antigen
for assessing T cell immunity in infection or vaccination
(Kaech et al., 2002; Murali-Krishna et al., 1998; Rodriguez et
al., 1997; Rodriguez and Whitton, 2000). Unlike HIV-1
gp120, LCMV NP is a cytosolic protein and the NP peptide
(NP118–126) is presented by the Ld allele (MHC class I) ofBALB/c mice for CD8+ T cell activation Rodriguez et al.,
1997). Four groups of mice were used in this series of
experiments (Fig. 6A) and carried out as explained in the
Figs 2 and 3 except that HIV gp120 DNA has been replaced
with LCMV-NP DNA. The frequencies of NP-specific CD8+
T cells were monitored in PBMC of the control and
vaccinated mice (Figs. 6B, C). It is clear that the mice in
group D, which received two injections of FLex DNA via
both i.v. and i.m. as in group E for gp120 DNA (Fig. 3A),
harbored 2- to 4-fold significantly higher frequencies of the
Fig. 4. The timing of vaccination during the DC expansion phase determines the frequency of antigen-specific T cells. (A) Immunization and analysis schedule: The
protocol for DC expansion and DNA immunization is the same as described under the legend to Fig. 2, with the exception that the timing of primary DNAvaccination
was varied (days 0, 3, 5, 7, and 0) after FLex DNA injection. We therefore used five groups of mice (day 0, day 3, day 5, day 7 and day 10) in the vaccination
experiments, and CD8+ T cells expressing INF-γ were analyzed at day 12 after a booster injection with gp120 DNA (5 mice per group). (B) The percentage of CD8+ T
cells making IFN-γ: representative flow plots from each group displaying percentage of CD8+ T cells making IFN-γ. (C) The average frequencies of gp120-specific
CD8+ T cells in each group of mice. The bar represents the standard error of the mean. Representative data from one experiment (of two repeat) are presented.
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after a booster injection. As expected, control vector did not
induce any NP-specific CD8+ T cells, and the NP DNA
vaccine encoding ubiquitinated NP (group C) induced 2-fold
higher numbers of NP-specific CD8+ T cells compared to its
counterpart, the unmodified native NP protein (group B).
Although the DC numbers are 7- to 8-fold higher in PBMC
of Flex DNA treated mice (Fig. 1A), we have consistently
observed only 3- to 4-fold increases in the frequencies of
antigen-specific CD8+ T cells in the immunized mice (Figs. 3
and 6).Discussion
In the present study, we have tested the hypothesis that large
numbers of DCs could enhance the immunogenicity of DNA
vaccines, and provide evidence that mere increases in the
number of DCs at the time of DNA immunization are not
sufficient to induce enhanced levels of immune response.
Interestingly, however, co-delivery (i.m.) of FLex DNA with
DNAvaccines was required to reveal the adjuvant activity of the
FLex protein expressed from plasmid DNA in mice harboring
large numbers of DCs in various tissues. That is, two injections
Fig. 5. Persistence of high frequencies of memory T cells depends on the burst size at the primary phase of the immune response. Mice in groups B, D, and E are rested
for 60 days after the booster injection (Fig. 3A) and PBMC obtained from individual mice were pulsed for the presence of gp120-specific CD8+ T cells. (A)
Representative flow plot displaying the percentage of CD8+ T cells making IFN-γ. (B) The average frequencies of gp120-specific CD8+ T cells in each group of mice.
The bar represents the standard error of the mean (P < 0.05). Representative data from one experiment (of two repeats) are presented.
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DNA vaccines, i.m.) were needed to reveal the immune
enhancing effects of FLex DNA in genetic vaccination (Figs.
3 and 6). The kinetic data further suggest that there is a critical
time window during the DC expansion phase, beyond which
this effect is only minimal or negligible. For example, DNA
vaccines induced heightened levels of immune responses within
the period of DC expansion (from day 0 to day 7), and the
vaccine delivered at day 10 after the injection of FLex DNA
induced the frequency of CD8+ T cells that are comparable to
that induced by the vaccines in mice that received only one
FLex DNA injection (Fig. 4). This timeframe is likely to
coincide with the expression kinetics of vaccine antigens in
vivo.
In vitro transfected systems, the optimal expression of genes
under the control of the CMV promoter is achieved in 3 days
(72 h), and it is likely that similar kinetics occur in the
vaccinated sites. Accordingly, the timing of vaccine antigen
expression and quantitative (number) and qualitative (cytokines
and chemokines) state of DCs in vivo would be critical to access
and to activate the antigen-processing machinery of DCs. Our
kinetic data suggest that the quantitative and qualitative
properties of the immune cells (DCs) would have positive
impact on the enhanced levels of immune responses (Fig. 4).
Furthermore, this immune enhancement was observed for twodifferent viral proteins (HIV-1 gp120 and LCMV-NP), having
distinct biosynthetic pathways. For example, gp120 is a secreted
protein, and NP is predominantly cytosolic, but both induce
similar levels of immune enhancement, indicating that the
endogenous (direct) and exogenous (indirect, cross-presenta-
tion) antigen-presenting pathways could be operational in
activating T cells (Bhardwaj, 2001; Ackerman and Cresswell,
2004; Leifert et al., 2004).
What is the mechanism by which plasmid-encoded FLex acts
as an adjuvant in genetic vaccination? DCs as “natural
adjuvant” would be the primary cell type, having a predominant
role in processing vaccine-encoded antigens for T cell
activation. However, we have shown that a mere increase in
DC numbers alone was not sufficient to induce high frequencies
of antigen-specific CD8+ T cells. Also, a single injection of
FLex DNA at the vaccination site (i.m.) has not induced higher
levels of CD8+ T cells. Our results are consistent with the Sang
et al. (2003) study, in that a single i.m. delivery of FLex DNA
failed to induce enhanced levels of INF-γ secreting HIV-1 Gag-
specific spleen cells, but FLex DNA formulated in SP1017, a
pluronic carrier, was robust in the induction of Gag-specific
immune responses (Sang et al., 2003). Interestingly, the authors
have shown that a large number of DCs are recruited to the
regional lymph nodes and muscle cells in response to the
formulated FLex DNA, and this is correlated with its adjuvant
Fig. 6. DC expansion prior to co-injection (i.m.) of LCMV-NP DNA and Flex DNA is required for the enhancement of NP-specific CD8+ T cell responses: The
protocol for DC expansion and DNA immunization is the same as described under the legend to Fig. 2. PBMC of the immunized mice were pulsed with NP 118–126 as
described by Rodriguez et al. (1997) under similar conditions described for the gp120 peptide (Sailaja et al., 2003) to identify NP-specific CD8+ T cells. (A)
Experimental groups, (B) Representative flow plots from each group displaying the percentage of CD8+ T cells making IFN-γ. (C) The average frequencies of NP-
specific CD8+ T cells in each group of mice. The bar represents the standard error of the mean (P < 0.05). Representative data from one experiment (of two repeats) are
presented.
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encoding Flt-3 L and GM-CSF were co-delivered, inducing
enhanced levels of antigen-specific CD4+ T cell responses in
mice or out-bred calves (Mwangi et al., 2002; Peretz et al.,
2002). Thus, FLex DNAwith SP1017 or GM-CSF appears to be
a potent inducer of DC mobilization in vivo at the vaccination
site or LN (Mwangi et al., 2002; Peretz et al., 2002; Sang et al.,
2003).
Although we have not assessed the mobilization DCs in the
vaccination site (i.m.), it is conceivable that such mobilization
does occur in vivo, given the observation of the robust
expansion and mobilization of DCs in a number of other tissue
compartments in mice (Fig. 1A). The same principles couldoperate in other experimental model systems where plasmid
encoded Flt-3 L or Flt-3 fusion vaccines have been shown to
induce high frequencies of HIV-specific or tumor-specific
immune responses (Fong and Hui, 2002; Hung et al., 2001;
Moore et al., 2002; Sailaja et al., 2003). It is interesting to note
that the Sumida et al. (2004) study has also revealed that Flt-3 L
DNA could act as an adjuvant by enhancing immunogenicity of
a DNA vaccine, gp120 DNA, when injected with the plasmid
expressing MIP-1α. Importantly, this immune enhancement is
primarily due to the local recruitment and expansion of DCs to
the vaccination sites (Sumida et al., 2004), providing critical
mechanistic insight into the adjuvant effects of Flt-3 ligand
mobilized DCs in vivo. Thus, these studies have demonstrated
286 B.P. Nayak et al. / Virology 348 (2006) 277–288that plasmid-encoded FL or FLex could function as an effective
adjuvant to DNA vaccines or peptides under different condi-
tions of its delivery (alone or in combination with other
cytokines) to animals.
We are still left with the puzzle about the mechanism of FL
or FLex action because of the nature of expression of its
receptor and other unresolved issues. Since the receptor (Flt-3
or flk-2) for Flt-3 ligand has restricted expression on
hematopoietic stem cells (HSC) or other common progenitors,
it is not clear as to how FL expressed in muscle cells (i.m.) or
the skin (i.d.) would recruit or expand DC as immature DC in
the periphery are devoid of any discernable Flt-3 expression
(Hannum et al., 1994; Lyman et al., 1994, Sitnicka et al.,
2002). Skeletal muscle cells harbor HSC (Kawada and Ogawa,
2001; McKinney-Freeman et al., 2002), but the role of such
local HSC in vaccine-induced immunity is unclear. If these
cells expressed Flt-3, it is tempting to speculate that
engagement of this receptor by Flt-3 L could induce signaling
cascades resulting in activation of genes involved in innate
immunity (Zhang et al., 2000). It is an intriguing possibility,
given the role of FLex and/or GM-CSF in inducing an
expansion and mobilization of DCs to the sites (i.m. or i.d.) of
plasmid injection (Mwangi et al., 2002; Peretz et al., 2002;
Sang et al., 2003; Westermann et al., 2004).
Production of gp120-specific antibodies indicate CD4 help
in vaccinated mice (Kaech et al., 2002). Plasmid-encoded
antigens could utilize both direct and indirect antigen-present-
ing pathways to induce CD8+ T cells. The direct, endogenous
pathway depends on the processing of plasmid-encoded
antigens in the cytoplasm-ER axis and the indirect, exogenous
pathway (cross-presentation) is responsible for processing
antigens acquired from outside the cell for presentation to
CD8+ T cells. The CD8αpositive and CD8αnegative DC popula-
tions are capable of antigen presentation using either of the
pathways (Ackerman and Cresswell, 2004; den Haan and
Bevan, 2002; Ingulli et al., 2002). The uptake of HIV-1 gp120
and LCMV-NP by these DCs is possible in vivo to elicit
antigen-specific CD8+ T cell and antibody responses, respec-
tively. Efforts to maximize the efficiency of DC function in vivo
using other DC growth factors and TLR ligands (Pulendran,
2004 would provide insights into design of DNA vaccines
capable of inducing robust immunity.
Materials and methods
Generation of gene constructs expressing HIV-1 gp120 and
hFLex
The plasmid DNA encoding the HIV-1 envelope glycopro-
tein (Karlsson et al., 1997) gp120 (SHIV89.6P), was generated
by cloning a PCR fragment in-frame with that coding for tissue
plasminogen transactivator (tPA) ER signal in the vector,
pJW4303. The gp120 portion (nucleotide: 100 to 1512) of
SHIV89.6p envelope was amplified using the following primers:
(a) gp120 5′ Nhe: (5′-TGC GGC GCC GCT AGC TTG TGG
GTC ACA GTC TAT TAT GG-3′) and gp120 3′ Bam: (5′-AAG
CGG ATC CAT CAC ACT GTT CTT CTC TTT GCC CTC-3′). We carried the amplification protocol as described earlier
(Nayak et al., 2003; Sailaja et al., 2003). The plasmid DNA
encoding hFLex was obtained from the National Gene Vector
Laboratory (University of Michigan, Ann Arbor, MI). The
plasmids, pCMV-NP and pCMV-U-NP (Rodriguez et al.,
1997), encoding respectively lymphocytic choriomeningitis
virus (LCMV) wild type nucleoprotein (NP) and an ubiquitin-
conjugated NP were gifts from Lindsey Whitton (Scripps
Institute, San Diego, USA) via Rafi Ahmed (Emory University,
Atlanta, USA). To detect expression of HIV-1 gp120 and
hFLex, 1.5 × 106 293-T cells, were transfected with pJW-gp120
and pNGVL-hFLex according to the manufacturer's instruc-
tions (Invitrogen, CA). Detergent lysates and medium super-
natants were prepared for protein analysis and Western blots
were carried out as described previously (Nayak et al., 2003;
Sailaja et al., 2003).
Animals, DNA injections, and immunization regimen
Female BALB/c (6–8 weeks old) were purchased from
Charles River via the NCI Frederick Cancer Facility and
maintained in the vivarium at the Yerkes National Primate
Research center (Atlanta, GA) according to the Institutional
Animal Care and Use Committee guidelines. Age-matched
mice were used to induce DC expansion in vivo and for DNA
vaccination to assess the effects of FLex expression in immune
responses. To induce DC expansion, a single i.v. injection of
FLex DNA (10 μg/1.6 ml of saline) was administered as
described previously (Liu et al., 1999) and to vaccinate, the
plasmid expressing gp120 or FLex (100 μg/mouse) or both
were injected intramuscularly (i.m.) into each of the tibialis
anterior muscles at a concentration of 1 μg/μl in 50 μl PBS (pH
7.4). For booster injections, each mouse was given gp120 DNA
(i.m., 100 μg) at day 35 after primary immunization. Blood was
drawn from the retro-orbital plexus on days 14 and 30 after
primary immunization, and day 12 after a booster injection to
perform the intracellular cytokine (ICC) assay in PBMC and
sera for measurement of antibody titers.
Analysis of FLex DNA-induced DC expansion by FACS
Spleen, bone marrow (BM), lymph nodes (LN) and PBMC
were collected and pooled (n = 3 each) from control (vector) and
treated (FLex DNA) mice to make single-cell suspensions,
which were counted after a lysis procedure to remove RBC. The
cells were incubated with FC block (clone: 2 4G2 at 5 μg/ml) to
prevent non-specific binding of antibodies to Fc-receptors and
then stained with specific antibodies to CD11b [CD11b-
allophycocyanin (M1/70)], CD11c [CD11c-PE (HL3)], CD3
[CD3-PerCP (145-2C11)], and B220 [B220 PerCP (RA3-
6B2)]. An aliquot of these cells was stained in parallel for the
surface markers, CD1d (1B1), CD8a (53–6.7), DEC205
(NLDC145), CD80 (16-10A1), CD86 (GL1), MHC II (2G9)
and appropriate isotypes conjugated to FITC. All the antibodies
were purchased from Pharmingen, (USA) except for the clone,
NLDC145, (DEC205, Calbiochem(USA). Staining was carried
out on ice for 20 min in FACS buffer (100 μl; D-PBS in 1%
287B.P. Nayak et al. / Virology 348 (2006) 277–288BSA plus 0.2% sodium azide), washed twice with the same
buffer before fixing in 1% paraformaldehyde (200 μl). The cells
were gated on the CD11c+ population to assess the number of
DCs in control (vector) and FLex DNA (DC expansion) treated
mice. Samples were acquired in a FACScalibur (BD Bios-
ciences, Mountain View, CA) and analyzed on FlowJo 3.4.
(Tree Star, San Carlos, CA).
Preparation of PBMCs and Intracellular cytokine (ICC) assay
Blood was drawn from control and DNA vaccinated mice
through orbito-plexus into sterile tubes containing heparin (5 U/
ml) in PBS. PBMCs were separated and ICC was performed as
described previously (Belyakov et al., 1998; Nayak et al., 2003;
Sailaja et al., 2003).
ELISA
To detect anti-gp120 antibody titers, we performed capture
ELISA as described previously (Nayak et al., 2003; Sailaja et
al., 2003) with sera separated from control and DNAvaccinated
mice.
Statistical analysis
In all animal experiments, we used 3–5 mice per group. For
antibody titers, we used pooled sera from 5 mice. All statistical
analysis was performed by one-way ANOVA (one-way analysis
of variance) with Tukey's post-test for multiple samples using
GraphPad Prism version 4.00 for Windows, GraphPad
Software, San Diego, CA, USA, http://www.graphpad.com. A
value of P < 0.05 was considered significant.
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